Optimizing the Treatment of Patients With Multiple Myeloma and Renal Impairment

Norbert Grząśko(Lublin Oncology Center), Marek Hus(Medical University of Lublin), Marta Morawska(Lublin Oncology Center)

Clinical Lymphoma Myeloma & Leukemia

October 5, 2014

10.1016/j.clml.2014.09.012

Cited by 30

Related Papers

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

|New England Journal of Medicine|2024|162

Thalidomide treatment of resistant or relapsed multiple myeloma patients.

|PubMed|2001|85

Therapy‐related peripheral neuropathy in multiple myeloma patients

|Hematological Oncology|2014|70

Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis

|Leukemia|2022|63

Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma

|Annals of Hematology|2011|62